Treatment of cholestatic liver disease
Bylvay may not be effective in PFIC type 2 patients with ABCB11 variants resulting in non-functional or complete absence of bile salt export pump protein (BSEP-3).
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A05 BILE AND LIVER THERAPY
A05A BILE THERAPY
A05AX Other drugs for bile therapy
A05AX05 Odevixibat
D11716 Odevixibat (USAN) <US>
USP drug classification [BR:br08302]
Gastrointestinal Agents
Gastrointestinal Agents, Other
Odevixibat
D11716 Odevixibat (USAN)
Drug groups [BR:br08330]
Transporter substrate
DG01665 ABCB1 substrate
D11716 Odevixibat
Target-based classification of drugs [BR:br08310]
Transporters
Solute carrier family
SLC10
SLC10A2 (ASBT, IBAT)
D11716 Odevixibat (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11716
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11716
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11716
Drug metabolizing enzymes and transporters [br08309.html]
Drug transporters
D11716
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D11716